Altre lingue Adlai Nortye Ltd.

Azioni

ANL

US00704R1095

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 28/06/2024			Variaz. 5gg	Var. 1 gen.
3,26 ^USD	-12,12%		-10,68%	-63,74%

24/05	Adlai Nortye Ltd. annuncia di presentare i dati incoraggianti della combinazione di AN0025 e chemoradioterapia definitiva (dCRT) all'ASCO 2024	CI
22/05	Adlai Nortye annuncia il dosaggio del primo paziente nello studio clinico randomizzato di Fase Ii di Palupiprant (An0025) per il trattamento del tumore rettale localmente avanzato con radioterapia	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Adlai Nortye : U.S. Securities and Exchange Commission Form 6 K	27/06
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024	24/05
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024	24/05
Adlai Nortye Ltd. Announces to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy At ASCO 2024	24/05
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy	22/05
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy	22/05
Adlai Nortye Announces First Patient Dosed in Randomized Phase Ii Clinical Trial of Palupiprant for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy	22/05
ADRs Advance, Eco Wave Power Global AB Climbs 213.4%	08/04
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development	01/04
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development	29/03
Adlai Nortye Announces Appointment of Archie Tse as the Head of Research & Development	29/03
Certain Class B Ordinary Shares of Adlai Nortye Ltd. are subject to a Lock-Up Agreement Ending on 28-MAR-2024.	28/03
Certain Class A Ordinary Shares of Adlai Nortye Ltd. are subject to a Lock-Up Agreement Ending on 28-MAR-2024.	28/03
Adlai Nortye : Term of use	06/12
Adlai Nortye Says it has Completed Patient Enrollment in Phase 3 Trial of Buparlisib	17/11
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC	17/11
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC	17/11
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC	17/11
Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award	23/10/23
Adlai Nortye : in collaboration with Nucleai, to Present "Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN" at ESMO 2023	16/10/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Adlai Nortye Ltd.

Azioni

ANL

US00704R1095

Altre lingue

Filtri